JP2021502347A - ゲムシタビンを使用した膀胱癌の治療及び維持療法の方法 - Google Patents

ゲムシタビンを使用した膀胱癌の治療及び維持療法の方法 Download PDF

Info

Publication number
JP2021502347A
JP2021502347A JP2020524573A JP2020524573A JP2021502347A JP 2021502347 A JP2021502347 A JP 2021502347A JP 2020524573 A JP2020524573 A JP 2020524573A JP 2020524573 A JP2020524573 A JP 2020524573A JP 2021502347 A JP2021502347 A JP 2021502347A
Authority
JP
Japan
Prior art keywords
individual
gemcitabine
period
delivery
bladder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020524573A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021502347A5 (https=
Inventor
ギーシング，デニス
キューティー，クリストファー
Original Assignee
タリス バイオメディカル エルエルシー
タリス バイオメディカル エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by タリス バイオメディカル エルエルシー, タリス バイオメディカル エルエルシー filed Critical タリス バイオメディカル エルエルシー
Publication of JP2021502347A publication Critical patent/JP2021502347A/ja
Publication of JP2021502347A5 publication Critical patent/JP2021502347A5/ja
Priority to JP2023173773A priority Critical patent/JP2024009888A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
JP2020524573A 2017-11-08 2018-11-07 ゲムシタビンを使用した膀胱癌の治療及び維持療法の方法 Pending JP2021502347A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023173773A JP2024009888A (ja) 2017-11-08 2023-10-05 ゲムシタビンを使用した膀胱癌の治療及び維持療法の方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762583394P 2017-11-08 2017-11-08
US62/583,394 2017-11-08
PCT/US2018/059698 WO2019094517A1 (en) 2017-11-08 2018-11-07 Methods of treatment and maintenance therapy for bladder cancer using gemcitabine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023173773A Division JP2024009888A (ja) 2017-11-08 2023-10-05 ゲムシタビンを使用した膀胱癌の治療及び維持療法の方法

Publications (2)

Publication Number Publication Date
JP2021502347A true JP2021502347A (ja) 2021-01-28
JP2021502347A5 JP2021502347A5 (https=) 2022-01-04

Family

ID=66439297

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020524573A Pending JP2021502347A (ja) 2017-11-08 2018-11-07 ゲムシタビンを使用した膀胱癌の治療及び維持療法の方法
JP2023173773A Pending JP2024009888A (ja) 2017-11-08 2023-10-05 ゲムシタビンを使用した膀胱癌の治療及び維持療法の方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023173773A Pending JP2024009888A (ja) 2017-11-08 2023-10-05 ゲムシタビンを使用した膀胱癌の治療及び維持療法の方法

Country Status (18)

Country Link
US (3) US10792297B2 (https=)
EP (1) EP3706763A4 (https=)
JP (2) JP2021502347A (https=)
KR (3) KR102892737B1 (https=)
CN (1) CN111787926A (https=)
AU (1) AU2018366106B2 (https=)
BR (1) BR112020008700A2 (https=)
CA (1) CA3081839A1 (https=)
DO (1) DOP2023000155A (https=)
EA (1) EA202091143A1 (https=)
IL (2) IL302714B1 (https=)
JO (1) JOP20200124A1 (https=)
MA (1) MA50581A (https=)
MX (2) MX2020004771A (https=)
PE (1) PE20210041A1 (https=)
PH (1) PH12020550587A1 (https=)
SG (1) SG11202003950WA (https=)
WO (1) WO2019094517A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT4124339T (lt) 2014-03-06 2025-11-10 Vaisto įvedimo sistemos ir būdai šlapimo pūslės vėžiui gydyti gemcitabinu
BR112020000832A2 (pt) 2017-07-25 2020-07-21 Taris Biomedical Llc métodos para tratar metástase tumoral
JOP20200124A1 (ar) * 2017-11-08 2020-05-20 Taris Biomedical Llc طُرق لعلاج سرطان المثانة باستخدام جيمسيتابين وعلاج مدوامة لذلك
WO2024092159A1 (en) * 2022-10-28 2024-05-02 Taris Biomedical Llc Methods of treating bladder cancer with gemcitabine

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015512914A (ja) * 2012-03-29 2015-04-30 アルター・バイオサイエンス・コーポレーション 新生物を治療するための方法
JP2017508749A (ja) * 2014-03-06 2017-03-30 タリス バイオメディカル エルエルシー 薬物送達システム及びゲムシタビンによる膀胱がんの治療方法

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4111203A (en) 1976-11-22 1978-09-05 Alza Corporation Osmotic system with means for improving delivery kinetics of system
US6171298B1 (en) 1996-05-03 2001-01-09 Situs Corporation Intravesical infuser
AU2003278881A1 (en) 2002-09-23 2004-04-08 Microchips, Inc. Micro-reservoir osmotic release systems and microtube array device
CA2503193A1 (en) 2002-10-22 2004-05-06 The Biomerix Corporation Method and system for intravesicular delivery of therapeutic agents
US8361490B2 (en) 2004-09-16 2013-01-29 Theracoat Ltd. Biocompatible drug delivery apparatus and methods
DK1933810T3 (da) 2005-08-11 2013-01-28 Childrens Medical Center Intravesikal lægemiddelafgivelsesindretning og fremgangsmåde
WO2007145704A2 (en) 2006-04-24 2007-12-21 Gloucester Pharmaceuticals Gemcitabine combination therapy
EP1913962A1 (en) 2006-10-22 2008-04-23 Ophir Perelson Expandable medical device for the treatment and prevention of cardiovascular diseases
KR101538748B1 (ko) 2007-12-11 2015-07-22 메사추세츠 인스티튜트 오브 테크놀로지 이식형 의약 투여 장치와 방광과 기타 신체 낭 또는 내강의 치료 방법
CA2720523C (en) 2008-04-04 2013-12-17 Lipella Pharmaceuticals, Inc. Treatment of bladder dysfunction using liposomal botulinum toxin
EP2313122B1 (en) 2008-07-17 2019-03-06 Micell Technologies, Inc. Drug delivery medical device
EA201170297A1 (ru) 2008-08-09 2011-08-30 Массачусетс Инститьют Оф Текнолоджи Имплантируемое устройство для доставки лекарственных средств и способ лечения мужской мочеполовой системы и окружающих тканей
DK2445570T3 (da) 2009-06-26 2013-02-25 Taris Biomedical Inc Implanterbare lægemiddelafgivelsesindretninger samt fremgangsmåder til deres fremstilling
US9017312B2 (en) 2009-09-10 2015-04-28 Taris Biomedical Llc Implantable device for controlled drug delivery
US8721621B2 (en) 2009-09-10 2014-05-13 Taris Biomedical, Inc. Systems and methods for deploying devices to genitourinary sites
PL3884988T3 (pl) 2009-12-17 2025-09-08 Taris Biomedical Llc Urządzenie implantowalne z tolerancją wewnątrzpęcherzową
ES2732150T3 (es) 2010-01-20 2019-11-20 Urogen Pharma Ltd Material y método para tratar cavidades internas
US20110218488A1 (en) 2010-03-05 2011-09-08 Taris Biomedical, Inc. Systems and Methods for Implanting Devices in the Bladder and Other Genitourinary Sites
WO2011153009A1 (en) 2010-06-02 2011-12-08 Abraxis Bioscience, Llc Methods of treating bladder cancer
EP3795121A1 (en) 2010-08-05 2021-03-24 TARIS Biomedical LLC Ureteral stent drug delivery device
US9457176B2 (en) 2010-10-06 2016-10-04 Taris Biomedical Llc Implantable drug delivery device with bladder retention feature
WO2012048114A1 (en) 2010-10-06 2012-04-12 Taris Biomedical, Inc. Time-selective bioresorbable or collapsible drug delivery systems and methods
MX365807B (es) 2010-10-27 2019-06-14 Prometic Pharma Smt Ltd Compuestos y composiciones para el tratamiento del cáncer.
WO2012079083A2 (en) 2010-12-10 2012-06-14 The Board Of Regents Of The University Of Nebraska Hemodialysis catheter with displaceable tubes to disrupt a fibrous sheath
US8979797B2 (en) 2010-12-16 2015-03-17 Ams Research Corporation High pressure delivery system and method for treating pelvic disorder using large molecule therapeutics
JP2014503554A (ja) 2011-01-10 2014-02-13 タリス バイオメディカル，インコーポレイテッド 膀胱痛及び刺激性排尿の持続的治療の使用のためのリドカインレジメン
EP2670398B1 (en) 2011-02-04 2017-06-07 TARIS Biomedical LLC Implantable device for controlled release of low solubility drug
US20150005595A1 (en) 2011-12-30 2015-01-01 Kibur Medical, Inc. Implantable devices and methods for evaluation of active agents
WO2013170069A1 (en) 2012-05-09 2013-11-14 Massachusetts Institute Of Technology Medicament, method, and drug delivery device for treatment of ovarian cancer
MX367070B (es) 2012-08-31 2019-08-05 Taris Biomedical Llc Sistemas de administracion de farmaco y metodos para el tratamiento de la prostata.
SG11201501424SA (en) 2012-08-31 2015-03-30 Taris Biomedical Llc Drug delivery systems and methods for treatment of bladder cancer comprising oxaliplatin
JP2016508842A (ja) 2013-03-05 2016-03-24 タリス バイオメディカル エルエルシー 装置の開口部を通じて制御された薬物放出のための薬物送達装置及び方法
KR102557326B1 (ko) 2013-03-15 2023-07-19 타리스 바이오메디컬 엘엘씨 약물-투과성 구성요소를 가지는 약물 전달 장치
EP2968120B1 (en) 2013-03-15 2026-01-14 TARIS Biomedical LLC Drug delivery devices and methods for drug delivery
CA2944480C (en) 2013-04-10 2021-05-18 Massachusetts Institute Of Technology Local drug delivery devices and methods for treating cancer
DE102013103986A1 (de) 2013-04-19 2014-10-23 B. Braun Avitum Ag Rezirkulationsvorrichtung eines extrakorporalen Blutbehandlungsgeräts
KR102385603B1 (ko) 2013-08-19 2022-04-11 타리스 바이오메디컬 엘엘씨 다중 유닛 약물 전달 장치 및 방법
US9215250B2 (en) 2013-08-20 2015-12-15 Janus Technologies, Inc. System and method for remotely managing security and configuration of compute devices
EP3065807A1 (en) 2013-11-05 2016-09-14 TARIS Biomedical LLC Osmotic drug delivery devices, kits, and methods
RU2591946C2 (ru) 2014-06-24 2016-07-20 Владимир Эдуардович Анников Способ изготовления гелеобразного водосодержащего взрывчатого состава
KR20220061253A (ko) 2014-06-26 2022-05-12 타리스 바이오메디컬 엘엘씨 탄성 폴리머-약물 매트릭스 시스템을 포함하는 방광내 약물 전달 장치 및 방법
WO2016172704A1 (en) 2015-04-23 2016-10-27 Taris Biomedical Llc Drug delivery devices with drug-permeable component and methods
CN118453872A (zh) 2016-05-06 2024-08-09 塔里斯生物医药公司 治疗下尿路尿道上皮癌的方法
BR112020000832A2 (pt) 2017-07-25 2020-07-21 Taris Biomedical Llc métodos para tratar metástase tumoral
JOP20200124A1 (ar) 2017-11-08 2020-05-20 Taris Biomedical Llc طُرق لعلاج سرطان المثانة باستخدام جيمسيتابين وعلاج مدوامة لذلك
CN112839653A (zh) 2018-08-01 2021-05-25 塔里斯生物医药公司 使用曲司氯铵治疗膀胱过度活动症的方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015512914A (ja) * 2012-03-29 2015-04-30 アルター・バイオサイエンス・コーポレーション 新生物を治療するための方法
JP2017508749A (ja) * 2014-03-06 2017-03-30 タリス バイオメディカル エルエルシー 薬物送達システム及びゲムシタビンによる膀胱がんの治療方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FRONTIERS IN ONCOLOGY, vol. 7, JPN6022041598, 2 November 2017 (2017-11-02), pages 260, ISSN: 0004888232 *
NCT02722538 SAFETY AND TOLERABILITY OFGEMRIS 225 MG IN SUBJECTS WITH MUSCLE-INVASIVE BLADDER CANCER,, JPN6022005795, ISSN: 0005076718 *
RADIOTHER. ONCOL. (2012) VOL.102, ISSUE3, P.412-415, JPN6022005792, ISSN: 0005076717 *

Also Published As

Publication number Publication date
MX2020004771A (es) 2020-10-19
IL274343B2 (en) 2023-10-01
IL302714A (en) 2023-07-01
EP3706763A1 (en) 2020-09-16
US20210085705A1 (en) 2021-03-25
US20190175637A1 (en) 2019-06-13
CN111787926A (zh) 2020-10-16
MA50581A (fr) 2020-09-16
PE20210041A1 (es) 2021-01-08
JP2024009888A (ja) 2024-01-23
US12029749B2 (en) 2024-07-09
MX2023007680A (es) 2023-07-07
WO2019094517A1 (en) 2019-05-16
BR112020008700A2 (pt) 2020-10-27
KR102892737B1 (ko) 2025-11-28
US10792297B2 (en) 2020-10-06
IL274343B1 (en) 2023-06-01
PH12020550587A1 (en) 2021-04-26
CA3081839A1 (en) 2019-05-16
US20230321129A1 (en) 2023-10-12
KR20240119176A (ko) 2024-08-06
KR20250174098A (ko) 2025-12-11
SG11202003950WA (en) 2020-05-28
JOP20200124A1 (ar) 2020-05-20
DOP2023000155A (es) 2023-12-29
AU2018366106A1 (en) 2020-05-14
EP3706763A4 (en) 2021-08-11
IL302714B1 (en) 2026-01-01
IL274343A (en) 2020-06-30
AU2018366106B2 (en) 2024-11-14
KR20200085822A (ko) 2020-07-15
EA202091143A1 (ru) 2020-07-30

Similar Documents

Publication Publication Date Title
JP7802743B2 (ja) 薬物送達システム及びゲムシタビンによる膀胱がんの治療方法
US10406335B2 (en) Drug delivery systems and methods for treatment of prostate
JP7520932B2 (ja) 腫瘍転移を処置する方法
JP2024009888A (ja) ゲムシタビンを使用した膀胱癌の治療及び維持療法の方法
EA045084B1 (ru) Способы лечения и поддерживающей терапии рака мочевого пузыря с использованием гемцитабина
RU2799546C2 (ru) Способы лечения метастаза опухоли
HK40042011A (en) Drug delivery systems and methods for treatment of prostate
NZ723303B2 (en) Drug delivery systems and methods for treatment of bladder cancer with gemcitabine

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211105

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211119

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220921

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221004

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221209

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230301

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230330

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230606

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250922

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251224